Capricor Therapeutics' rating was downgraded amid FDA inspection risks, regulatory uncertainty, and potential delays in ...

U.S. FDA successfully completed Pre-License Inspection; Company expects facility will meet all requirements to support ...

Capricor Therapeutics (NASDAQ:CAPR) shares dropped after the U.S. FDA inspected its San Diego manufacturing facility for the ...

Capricor Therapeutics (CAPR) announced the completion of the Food and Drug Administration’s pre-license inspection of its San ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

“This inspection outcome is a major regulatory milestone, particularly in a field where standards are exceptionally high,” said Linda Marbán, Ph.D., Capricor’s Chief Executive Officer.

"This inspection outcome is a major regulatory milestone, particularly in a field where standards are exceptionally high,” said Linda Marbán, Ph.D., Capricor's Chief Executive Officer. "It reflects ...

SAN DIEGO, June 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...

Investing.com -- Capricor Therapeutics Inc (NASDAQ: CAPR) stock tumbled 10.5% after the company announced that the FDA’s inspection of its San Diego manufacturing facility resulted in a Form 483 with ...